Short-course adjuvant trastuzumab will increase cure rates in patients with human epidermal growth factor receptor 2-positive breast cancer

Adjuvant trastuzumab in early HER2-positive breast cancer: Journeying towards the optimal duration of therapy in South Africa

“…The optimal duration of trastuzumab therapy in the adjuvant management of early HER2-positive breast cancer has been contentious for many years. [4][5][6][7] The standard of care has been to prescribe therapy over a 12-month period [8] based on the findings of the pivotal licensing trials, including the HERA trial, [2] as well as the NSABP B31 and NCCTG N9831 trials. [9] Importantly, it has since been noted that this treatment duration was selected arbitrarily.…”